Merck to Acquire Bio-Techne at $73 Per Share, Enterprise Value Approximately $11.3 Billion
Alina Collins
Germany's Merck KGaA will buy U.S. lab-tools maker Bio-Techne for $73 a share in an all-cash deal valued at roughly $11.3 billion — the first major acquisition under new CEO Kai Beckmann and an early test of his dealmaking credibility.
What exactly is Merck buying?
Bio-Techne, based in Minneapolis, sells lab tools and reagents to research institutions and drugmakers.
In plain terms = it doesn't make drugs — it makes the supplies that drug developers can't work without, the "selling shovels in a gold rush" business.
Merck is offering $73 per share, all cash, at an enterprise value of roughly $11.3 billion.
How big is the premium?
Reuters reported the price is a 36% premium over Bio-Techne's one-month volume-weighted average.
The Wall Street Journal, using Wednesday's closing price, put the premium at 24%.
This means → by either benchmark, Merck is paying a significant markup — a sign it views these assets as worth competing for.
Where is the money coming from?
Merck said it will fund the deal with a mix of existing cash and new debt.
This means → no new equity dilution for shareholders, but the balance sheet will take on meaningful leverage.
Post-close, investors will need to watch Merck's debt-repayment pace closely.
Can the deal actually close?
The acquisition still requires regulatory approval and a Bio-Techne shareholder vote.
This is the first major deal pushed through by new CEO Kai Beckmann since he took the helm.
In plain terms = whether it clears and integrates smoothly is the market's first scorecard for the new management team.
Content is for reference only, not financial advice.